Last update 01 Nov 2024

Hopp Pharmaceutical (Guangzhou) Co., Ltd.

Private Company|
2017|
Guangdong Sheng, China

Overview

Basic Info

Introduction
Harbour BioMed (Guangzhou) Co., Ltd. is a global biopharmaceutical company specialized in the research and development and commercialization of innovative medicines in the field of oncology and immune disorders.

Tags

Urogenital Diseases
Skin and Musculoskeletal Diseases
Eye Diseases
Monoclonal antibody
Recombinant protein

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Endocrinology and Metabolic Disease2
Neoplasms2
Immune System Diseases2
Hemic and Lymphatic Diseases1
Infectious Diseases1
Nervous System Diseases1
Top 5 Drug TypeCount
Monoclonal antibody3
Recombinant protein1
Top 5 TargetCount
CTLA4(Cytotoxic T-Lymphocyte-Associated Antigen 4)1
FcRn(IgG receptor FcRn large subunit p51)1
TSLP(Thymic stromal lymphopoietin)1
TNF-α(Tumor necrosis factor α)1

Related

4
Drugs associated with Hopp Pharmaceutical (Guangzhou) Co., Ltd.
Batoclimab
Target
FcRn
Mechanism
FcRn antagonists [+1]
Active Org.
Immunovant Sciences Ltd. [+10]
Originator Org.
HANALL BIOPHARMA Co., Ltd.HANALL BIOPHARMA Co., Ltd.
Active Indication
Myasthenia Gravis [+7]
Inactive Indication
Autoimmune Haemolytic Anaemias
Drug Highest PhaseNDA/BLA
First Approval Ctry. / Loc.-
First Approval Date-
Tanfanercept
Target
TNF-α
Mechanism
TNF-α inhibitors
Active Org.
Holopack Verpackungstechnik GmbH [+5]
Originator Org.
HANALL BIOPHARMA Co., Ltd.HANALL BIOPHARMA Co., Ltd.
Active Indication
Dry Eye Syndromes [+1]
Inactive Indication
Uveitis [+1]
Drug Highest PhasePhase 3
First Approval Ctry. / Loc.-
First Approval Date-
Porustobart
Target
CTLA4
Mechanism
CTLA4 inhibitors
Active Org.
Harbour BioMed (Suzhou) Co., Ltd.Harbour BioMed (Suzhou) Co., Ltd. [+3]
Originator Org.
Harbour BioMed (Shanghai) Co., Ltd.Harbour BioMed (Shanghai) Co., Ltd.
Active Indication
Hepatocellular Carcinoma [+6]
Inactive Indication-
Drug Highest PhasePhase 2
First Approval Ctry. / Loc.-
First Approval Date-
21
Clinical Trials associated with Hopp Pharmaceutical (Guangzhou) Co., Ltd.
NCT05790694 / RecruitingPhase 1
A Randomized, Double-blind, Placebo-controlled, Single-ascending-dose Phase I Clinical Study in Healthy Chinese Subjects to Evaluate the Safety, Tolerability and Pharmacokinetics of HBM9378 (SKB378) After Subcutaneous Administration.
NCT05332210 / RecruitingPhase 3
A Long-term Open-label Extension Study to Evaluate the Safety of HBM9161 (HL161) Subcutaneous Injection in Patients With Generalized Myasthenia Gravis
NCT05167071 / Not yet recruitingPhase 1
An Open-Label, Phase 1 Clinical Study to Evaluate the Safety, Tolerability, PK/PD and Preliminary Efficacy of HBM4003 in Combination With Toripalimab in Patients With Advanced NEN and Other Solid Tumors
100 Clinical Results associated with Hopp Pharmaceutical (Guangzhou) Co., Ltd.
Login to view more data
0 Patents (Medical) associated with Hopp Pharmaceutical (Guangzhou) Co., Ltd.
Login to view more data
100 Deals associated with Hopp Pharmaceutical (Guangzhou) Co., Ltd.
Login to view more data
100 Translational Medicine associated with Hopp Pharmaceutical (Guangzhou) Co., Ltd.
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 17 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Phase 1 Clinical
2
1
Phase 3 Clinical
NDA/BLA
1
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
Batoclimab
 ( FcRn )		Myasthenia Gravis
More
NDA/BLA
Tanfanercept
 ( TNF-α )		Dry Eye Syndromes
More
Phase 3
HBM-9378
 ( TSLP )		Asthma
More
Phase 1
Porustobart
 ( CTLA4 )		Neuroendocrine tumor of pancreas
More
Phase 1
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free